文献速递肿瘤 PET/CT放射性药物与辐射防护

18F-氟匹伐酸PET示踪剂成像短链脂肪酸代谢的临床转化:健康志愿者在进食与空腹状态下的安全性、生物分布与剂量测定

Clinical translation of 18F-fluoropivalate - a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-03-02

研究纳入24名健康志愿者(进食组12名、空腹组12名),评估18F-FPIA的安全性、生物分布与内照射剂量。所有受试者耐受良好,无不良事件;肝脏吸收剂量最高(0.070 ± 0.023 mGy/MBq),有效剂量为0.0154 mSv/MBq(SD ± 0.0010)。进食与空腹状态间生物分布及剂量学未见差异。

要点

  • 18F-FPIA在24名健康志愿者中安全性良好,未发生不良事件。
  • 肝脏吸收剂量最高(0.070 ± 0.023 mGy/MBq),有效剂量为0.0154 mSv/MBq(SD ± 0.0010)。
  • 进食与空腹组间生物分布及剂量学未见差异。

核心结论

  • 18F-FPIA具有良好的安全性、成像和剂量学特征,是追踪短链脂肪酸代谢的有前景的候选放射性示踪剂。

研究设计与样本

  • 研究纳入24名健康男性和女性志愿者,分为进食组12名和空腹组12名。
  • 受试者接受159.48 MBq(范围47.31-164.66 MBq)的18F-FPIA,放射化学纯度>99%。
  • 受试者接受详细多次全身PET/CT扫描,并采集静脉血进行放射性和放射性代谢物定量。
  • 通过定义感兴趣区推导个体和平均器官驻留时间,使用OLINDA 1.1计算有效剂量。

主要发现

  • 所有受试者均耐受18F-FPIA,无不良事件。
  • 注射后60分钟,超过90%的放射性示踪剂存在于血浆中。
  • 吸收剂量最高的器官为肝脏(0.070 ± 0.023 mGy/MBq)、肾脏(0.043 ± 0.013 mGy/MBq)、胆囊壁(0.026 ± 0.003 mGy/MBq)和膀胱(0.021 ± 0.004 mGy/MBq),其余组织摄取低。
  • 基于全部24名受试者平均器官驻留时间计算的有效剂量为0.0154 mSv/MBq(SD ± 0.0010)。
  • 进食与空腹受试者间生物分布或剂量学未见差异,尽管全身非酯化脂肪酸和肉碱水平反映了空腹和进食状态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fatty acids derived de novo or taken up from the extracellular space are an essential source of nutrient for cell growth and proliferation. Radiopharmaceuticals including 11C-acetate, and 18F-FAC (2-18F-fluoroacetate), have previously been used to study short-chain fatty acid (SCFA) metabolism. We developed 18F-fluoropivalate (18F-FPIA; 3-18F-fluoro-2,2-dimethylpropionic acid) bearing a gem-dimethyl substituent to assert metabolic stability for studying SCFA metabolism. We report the safety, biodistribution, and internal radiation dosimetry profile of 18F-FPIA in 24 healthy volunteers and the effect of dietary conditions. MATERIALS AND METHODS: Healthy volunteer male and female subjects were enrolled (n = 24), and grouped into 12 fed and 12 fasted. Non-esterified fatty acids (NEFA) and carnitine blood measurements were assessed. Subjects received 159.48 MBq (range, 47.31-164.66 MBq) of 18F-FPIA. Radiochemical purity was > 99%. Safety data were obtained during and 24 h after radiotracer administration. Subjects underwent detailed multiple whole-body PET/CT scanning with sampling of venous bloods for radioactivity and radioactive metabolite quantification. Regions of interest were defined to derive individual and mean organ residence times; effective dose was calculated using OLINDA 1.1. RESULTS: All subjects tolerated 18F-FPIA with no adverse events. Over 90% of radiotracer was present in plasma at 60 min post-injection. The organs receiving highest absorbed dose (in mGy/MBq) were the liver (0.070 ± 0.023), kidneys (0.043 ± 0.013), gallbladder wall (0.026 ± 0.003), and urinary bladder (0.021 ± 0.004); otherwise there was low tissue uptake. The calculated effective dose using mean organ residence times over all 24 subjects was 0.0154 mSv/MBq (SD ± 0.0010). No differences in biodistribution or dosimetry were seen in fed and fasted subjects, though systemic NEFA and carnitine levels reflected fasted and fed states. CONCLUSION: The favourable safety, imaging, and dosimetric profile makes 18F-FPIA a promising candidate radiotracer for tracing SCFA metabolism.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Dubash SR, Keat N, Kozlowski K, et al. Clinical translation of 18F-fluoropivalate - a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers. Eur J Nucl Med Mol Imaging. 2020. PMID: 32123971. doi:10.1007/s00259-020-04724-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。